Biosimilars Built with Comparability

Talia Biologics provides biosimilar CDMO services for sponsors developing monoclonal antibodies, Fc-fusion proteins, recombinant proteins, enzymes, hormones, complex biologics, and next-generation biosimilar products that require disciplined analytical similarity, process development, GMP manufacturing, drug product strategy, and CMC control.

Biosimilars are not simple copies. They are not generic biologics. They are complex biological products that must be developed through evidence, comparability, process control, and analytical depth. A biosimilar programme succeeds when the molecule, process, analytical package, formulation, manufacturing strategy, and regulatory narrative all support the same conclusion: the product is highly similar to the reference product, with no clinically meaningful differences in safety, purity, or potency.

That standard demands serious CDMO execution.

Talia Biologics was built for that kind of work.

From Taipei, Taiwan; Stuttgart, Germany; and Charlottetown, Prince Edward Island, Canada, Talia supports sponsors across Asia-Pacific, Europe, and North America with a biosimilar development model built around precision, practicality, and evidence. Taiwan gives us technical responsiveness and manufacturing agility. Stuttgart gives us process discipline, quality structure, and European regulatory seriousness. Charlottetown gives us a focused North American base for practical biomanufacturing, analytical support, animal health biologics, fermentation, and scalable supply planning.

Together, these strengths create a biosimilar CDMO platform designed for programmes that need more than capacity. They need a partner that understands comparability from the beginning.

Biosimilars built with comparability.
That is the Talia approach.

Why Biosimilars Need a Different CDMO Model

A biosimilar programme does not begin with the question, “Can we make the molecule?”

It begins with harder questions.

Can we understand the reference product deeply enough?
Can we match the critical quality attributes that matter?
Can we control glycosylation, charge variants, aggregation, potency, purity, impurities, and stability?
Can we build a process that stays consistent across scale?
Can we create an analytical package strong enough to support similarity?
Can we formulate the product in a way that supports the intended route and presentation?
Can we manufacture at a cost structure that makes the biosimilar commercially viable?

A biosimilar CDMO must think across the whole programme. Expression alone is not enough. Yield alone is not enough. A clean chromatogram alone is not enough. A biosimilar needs a complete CMC system: product understanding, process control, analytical evidence, drug product stability, documentation, and regulatory alignment.

Talia supports biosimilar sponsors by connecting these pieces early.

Many biosimilar programmes fail or stall because teams treat development in fragments. One group works on the cell line. Another works on purification. Another works on analytics. Another thinks about drug product later. Another handles regulatory writing after the technical path has already locked in. That sequence creates risk.

Talia works differently.

We treat biosimilar development as one integrated path from reference product understanding to GMP supply.

Talia Biosimilar CDMO Capabilities

Talia supports biosimilar development through a complete set of technical, analytical, manufacturing, and CMC capabilities.

Our biosimilar CDMO services include:

• Reference product analysis
• Biosimilar development strategy
• Cell line and expression system support
• Upstream process development
• Downstream purification development
• Process scale-up
• GMP drug substance manufacturing
• Drug product development
• Sterile fill-finish strategy
• Lyophilization cycle development
• Analytical similarity assessment
• Critical quality attribute mapping
• Glycosylation analysis
• Charge variant analysis
• Aggregation analysis
• Purity and impurity profiling
• Potency assay development
• Binding and functional assay support
• Stability-indicating method development
• Forced degradation studies
• Comparability studies
• Biosimilar CMC documentation support
• Tech transfer
• Clinical supply manufacturing
• Packaging, labeling, cold chain, and commercial readiness

Talia can support standard biosimilar categories, including monoclonal antibodies, insulin-like proteins, hormones, enzymes, cytokines, Fc-fusion proteins, antibody fragments, and recombinant therapeutic proteins. We also support more complex biosimilar and biobetter strategies where the sponsor needs thoughtful CMC planning before moving into expensive late-stage work.

Our model is useful for emerging biosimilar companies, regional biopharma companies, established pharmaceutical sponsors, animal health biologics companies, and platform companies that want to move from analytical understanding into controlled manufacturing.

Reference Product Understanding

A biosimilar programme begins with the reference product.

Before a sponsor can build a credible biosimilar, the team needs a clear view of the reference product’s critical quality attributes, variability, formulation, presentation, potency, impurity profile, and stability behavior.

Talia supports reference product assessment by helping sponsors define what must be measured, what methods must be developed, what lots should be compared, and which attributes may become programme-defining risks.

This may include analysis of:

• Primary structure
• Higher-order structure
• Glycosylation profile
• Charge variants
• Size variants
• Aggregation
• Fragmentation
• Purity
• Product-related impurities
• Process-related impurities
• Binding activity
• Functional activity
• Potency
• Stability
• Degradation products
• Formulation composition
• Container closure considerations

The goal is not to collect data for decoration. The goal is to understand what the biosimilar must match and where the reference product itself shows acceptable variability.

A biosimilar development path becomes more efficient when the reference product is understood early. Without that foundation, process development becomes blind. The programme may produce material, but it may not produce the right material.

Talia helps sponsors avoid that mistake.

Critical Quality Attribute Mapping

Critical quality attributes define the technical heart of a biosimilar programme.

For a biosimilar monoclonal antibody, CQAs may include glycosylation, Fc function, charge heterogeneity, aggregation, binding affinity, effector function, potency, purity, and stability. For a recombinant enzyme, the CQA map may focus on activity, structure, glycosylation, isoforms, aggregation, and degradation. For an Fc-fusion protein, the programme may need to control both receptor-binding activity and Fc-mediated characteristics.

Talia helps sponsors identify, measure, and prioritize CQAs based on the product’s mechanism, reference product profile, analytical data, process sensitivity, and regulatory expectations.

This matters because not every attribute carries the same weight. Some differences may be acceptable. Some require process correction. Some require additional analytical explanation. Some affect potency or safety directly. Some influence formulation and stability.

Talia’s biosimilar CDMO model uses CQA mapping to guide process development instead of treating analytics as a late-stage check.

That is how biosimilar work should be done.

Cell Line and Expression Strategy

Biosimilar development depends heavily on expression strategy.

The chosen host cell line, expression system, clone, media, feed strategy, culture conditions, and scale-up path can influence product quality. For mammalian biosimilars, small process differences can affect glycosylation, charge variants, aggregation, impurity burden, and potency. For microbial or yeast-expressed biosimilars, host-derived impurities, folding, processing, endotoxin, and downstream burden may define the development challenge.

Talia supports cell line and expression strategy for biosimilar programmes by connecting productivity with product quality.

High titre is useful only if the product profile supports similarity. A process that produces more of the wrong profile creates work, not progress.

Our team supports clone and process assessment with attention to:

• Productivity
• Product quality
• Glycosylation
• Charge profile
• Aggregation
• Impurity burden
• Scalability
• Media and feed performance
• Process robustness
• Downstream compatibility
• Comparability to reference product targets

The best biosimilar process is not always the highest-yielding early process. It is the process that can produce the right product consistently at the right scale and cost.

Upstream Process Development

Talia supports upstream process development for biosimilar programmes that require controlled, scalable, and similarity-driven manufacturing.

Upstream development may include media screening, feed optimization, culture parameter development, induction strategy where relevant, temperature shift strategy, oxygen transfer, pH control, harvest timing, productivity improvement, metabolite monitoring, and scale-down model development.

For biosimilars, upstream process development must do more than increase yield. It must support the target quality profile.

That means upstream conditions must be evaluated for their effect on key attributes such as glycosylation, charge variants, aggregation, product-related impurities, and potency. The process must create material that downstream purification can polish without fighting the product at every step.

Talia develops upstream processes with this in mind. We do not separate productivity from comparability.

For sponsors transferring an existing process, Talia can review batch data, process parameters, cell culture performance, product quality trends, and scale-up assumptions to identify risk before the next batch.

For sponsors starting earlier, Talia can help build the development plan around reference product targets and future GMP requirements.

Downstream Purification Development

Downstream purification is often where biosimilar programmes become difficult.

A biosimilar process must remove impurities while preserving the product profile needed for similarity. The purification process must control aggregates, fragments, host-cell proteins, residual DNA, leached Protein A where relevant, endotoxin where relevant, charge variants, and other product- or process-related impurities.

Talia supports downstream purification development for biosimilar programmes through capture, intermediate purification, polishing, concentration, buffer exchange, and final drug substance preparation.

Capabilities may include:

• Affinity capture
• Protein A chromatography
• Ion exchange chromatography
• Hydrophobic interaction chromatography
• Mixed-mode chromatography
• Size-based polishing
• Ultrafiltration and diafiltration
• Viral clearance strategy
• Aggregate reduction
• Host-cell protein reduction
• Residual DNA control
• Endotoxin reduction
• Buffer exchange
• Concentration
• Process scale-up
• Process robustness evaluation

The downstream process must be efficient, but efficiency cannot come at the cost of similarity. A purification step that improves yield but shifts product quality may not serve the biosimilar programme.

Talia evaluates downstream workflows by how they support the full product profile, not simply by recovery.

Analytical Similarity

Analytical similarity is the centre of biosimilar development.

Talia supports analytical similarity assessment through method development, method qualification, reference product comparison, batch-to-batch assessment, critical quality attribute analysis, forced degradation, stability-indicating methods, and comparability planning.

Analytical similarity may include:

• Primary structure confirmation
• Peptide mapping
• Intact mass analysis
• Higher-order structure
• Glycan profiling
• Charge variant analysis
• Size variant analysis
• Aggregation analysis
• Purity assessment
• Impurity profiling
• Binding assays
• Functional assays
• Potency assays
• Degradation analysis
• Stability comparison
• Formulation-related analysis

The analytical package must do more than show that the product looks close in a few assays. It must build a convincing technical picture.

Talia helps sponsors determine which assays matter, how data should be interpreted, where differences require process action, and where additional orthogonal methods may strengthen the comparability argument.

A strong biosimilar programme is built on analytical discipline. Talia makes that discipline central.

Potency Assay Development

Potency is one of the most important and most difficult areas in biosimilar development.

A biosimilar must demonstrate that its biological activity is highly similar to the reference product. Depending on the product, this may require binding assays, cell-based assays, enzyme activity assays, receptor activation assays, neutralization assays, effector function assays, or other mechanism-linked potency methods.

Talia supports potency assay development and strategy for biosimilar products where function must be measured clearly and consistently.

We help sponsors evaluate:

• Mechanism of action
• Relevant biological activity
• Assay format
• Reference standards
• Controls
• Variability
• Sensitivity
• Specificity
• Linearity
• Precision
• Suitability for comparability
• Suitability for release

A weak potency assay can slow the entire programme. It can make stability unclear, comparability uncertain, release difficult, and regulatory discussion harder than necessary.

Glycosylation and Charge Variant Control

For many biosimilars, glycosylation and charge variants become critical areas of development.

Glycosylation can influence effector function, clearance, stability, immunogenicity risk, and similarity. Charge variants can reflect deamidation, sialylation, C-terminal lysine processing, oxidation, clipping, and other structural or process-related differences. These attributes can be sensitive to cell line, culture conditions, media, feed strategy, harvest timing, purification, formulation, and storage.

Talia supports glycosylation and charge variant analysis as part of biosimilar process development and analytical similarity.

We help sponsors understand how upstream and downstream decisions influence the product profile. When a profile shifts away from the reference target, Talia can support process adjustment, analytical investigation, or comparability strategy.

Biosimilar development requires control over subtle differences. Glycan and charge profiles are often where subtle becomes serious.

Aggregation, Stability, and Degradation

Aggregation and degradation can define whether a biosimilar is viable.

A product may show acceptable similarity after purification but lose that profile during concentration, formulation, filtration, filling, freezing, thawing, lyophilization, storage, or shipping. Biosimilar development must therefore connect analytical similarity with stability and drug product behavior.

Talia supports aggregation analysis, forced degradation studies, stability-indicating method development, formulation screening, and degradation pathway assessment.

We help sponsors understand:

• Aggregate formation
• Fragmentation
• Oxidation
• Deamidation
• Clipping
• Charge shifts
• Potency loss
• Formulation sensitivity
• Container closure effects
• Temperature sensitivity
• Freeze-thaw behavior
• Light exposure sensitivity
• Mechanical stress sensitivity

A biosimilar product must remain similar, not only appear similar at one moment. Talia builds stability thinking into the programme early.

Drug Product Development for Biosimilars

Drug product strategy matters in biosimilar development because the final presentation must support clinical use, stability, quality, and commercial competitiveness.

Talia supports biosimilar drug product development for liquid and lyophilized products, vials, prefilled syringes, cartridges, autoinjector-ready formats, high-concentration subcutaneous presentations, ophthalmic biologics, and other sterile product formats where appropriate.

Drug product work may include:

• Formulation screening
• Excipient strategy
• Buffer selection
• pH optimization
• Concentration development
• Viscosity reduction
• Aggregation control
• Silicone oil compatibility
• Container closure evaluation
• Sterile filtration strategy
• Lyophilization cycle development
• Reconstitution assessment
• Extractables and leachables planning
• Container closure integrity planning
• Stability programme design

For many biosimilar programmes, the route and presentation affect commercial success.

Sterile Fill-Finish and Clinical Supply

Talia supports sterile fill-finish strategy and clinical supply manufacturing for biosimilar programmes.

Biosimilar sterile drug product may require vial filling, prefilled syringe filling, cartridge filling, lyophilization, small-batch clinical supply, visual inspection, labeling, packaging, cold chain, and release testing coordination.

Talia helps sponsors align drug product development with the intended clinical and commercial path.

Clinical supply must meet immediate study needs, but it should not create avoidable problems for later comparability or commercial readiness. A rushed fill-finish path can create issues with stability, extractables and leachables, particles, container closure, device compatibility, and supply continuity.

Talia supports fill-finish planning as part of the biosimilar CMC strategy, not as a disconnected final step.

Comparability Studies and Tech Transfer

Comparability is not limited to biosimilar-versus-reference analysis. It also matters when processes change, sites change, scales change, equipment changes, or drug product presentations change.

Talia supports comparability planning for biosimilar development, process scale-up, tech transfer, CDMO transition, formulation changes, container closure changes, and manufacturing site changes.

This may include:

• Analytical comparability
• Process comparability
• Scale comparability
• Site transfer comparability
• Drug product comparability
• Stability comparison
• Release method alignment
• Batch history review
• Risk assessment
• Documentation support

Biosimilar sponsors often need to move between development sites, pilot sites, GMP manufacturing sites, and fill-finish partners. Each move introduces risk. Talia helps structure the transfer so the programme does not lose its technical thread.

A biosimilar transfer should not be a restart. It should be a controlled continuation.

Biosimilar CMC Rescue

Talia supports biosimilar CMC rescue when a programme stalls, fails to match the reference product, loses process consistency, develops analytical gaps, or encounters drug product instability.

Common biosimilar rescue situations include:

• Similarity gaps
• Glycosylation mismatch
• Charge variant mismatch
• High aggregation
• Poor potency assay performance
• Weak analytical package
• Inconsistent yield
• Unstable formulation
• Poor purification recovery
• Failed scale-up
• Incomplete process history
• CDMO transition failure
• Clinical supply delay
• Regulatory questions
• Comparability uncertainty

Talia begins by reviewing the molecule, reference product data, process history, analytical methods, batch results, formulation data, deviations, quality package, and timeline. Then we identify which issues require process work, which require analytics, which require formulation changes, and which require clearer CMC strategy.

Not every stalled biosimilar is scientifically broken. Many are structurally disorganized.

Talia helps rebuild the structure.

Packaging, Labeling, Cold Chain, and Commercial Readiness

A biosimilar programme must eventually become a reliable supplied product.

Talia supports packaging, labeling, serialization planning, cold chain, kit assembly, clinical packaging, commercial-readiness planning, temperature-controlled shipping, stability-aligned distribution, and supply chain coordination.

For biosimilars, commercial readiness matters because cost, reliability, presentation, and supply continuity influence market access. A biosimilar must compete not only scientifically, but operationally.

Talia helps sponsors think through:

• Clinical packaging
• Commercial presentation
• Labeling strategy
• Serialization
• Aggregation
• Kit configuration
• Cold chain requirements
• Ultra-cold needs where relevant
• Temperature excursion risk
• Shipping validation
• Storage conditions
• Shelf-life strategy
• Device and presentation planning

The best biosimilar strategy connects development with real-world supply.

Biosimilars for Human and Animal Health

Talia supports biosimilar and biosimilar-like development for both human therapeutics and animal health biologics.

Human biosimilar programmes may include monoclonal antibodies, Fc-fusions, hormones, enzymes, cytokines, growth factors, and recombinant proteins. Animal health programmes may include veterinary biologics, recombinant therapeutic proteins, monoclonal antibody products, enzymes, vaccines, and biosimilar-like products adapted to species, dose, route, and market economics.

Animal health biologics require practical development strategy. A canine antibody product, livestock injectable, aquaculture biologic, poultry biologic, or companion animal therapy may not follow the same commercial or regulatory assumptions as a human product. Talia’s Prince Edward Island presence gives the company a strong North American base for animal health and applied biotechnology programmes that need disciplined but practical manufacturing support.

Biosimilar thinking can be valuable beyond traditional human biopharma. The same principles apply: understand the reference or target product, control the process, prove product quality, and build a reliable supply path.

Why Talia for Biosimilar CDMO Services

Talia Biologics supports biosimilar programmes with the seriousness they require.

We do not treat biosimilars as simple manufacturing projects. We treat them as evidence-driven CMC programmes where analytical similarity, process control, formulation, GMP manufacturing, drug product, and supply must align.

Choose Talia for biosimilar CDMO services because we support:

• Reference product understanding
• Critical quality attribute mapping
• Cell line and expression strategy
• Upstream process development
• Downstream purification development
• Analytical similarity
• Potency assay development
• Glycosylation and charge variant analysis
• Aggregation and stability control
• Drug product development
• Sterile fill-finish planning
• Lyophilization
• Comparability studies
• Tech transfer
• CMC rescue
• Clinical supply
• Packaging, labeling, cold chain, and commercial readiness

Talia brings together Taiwanese responsiveness, German process discipline, and Prince Edward Island practicality to support biosimilar sponsors across Asia-Pacific, Europe, and North America.

This combination matters. Biosimilar development requires speed, but not chaos. It requires discipline, but not bureaucracy. It requires practicality, but not shortcuts.

Partner with Talia

If you are developing a biosimilar, biobetter, recombinant protein, Fc-fusion, monoclonal antibody, enzyme, hormone, animal health biologic, or complex follow-on biologic, Talia can help define the development path.

To route your programme quickly, include your modality, reference product if applicable, development stage, target timeline, expected scale, expression system, current analytical package, formulation status, and any known comparability or process concerns.

Incomplete information is fine. Biosimilar programmes often begin with open questions. Talia helps turn those questions into a controlled CMC plan.

Biosimilars Built with Comparability.